iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Stock Short Interest Drops 68.9%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 67,932 shares, a decrease of 68.9% from the September 30th total of 218,618 shares. Based on an average daily volume of 164,313 shares, the short-interest ratio is presently 0.4 days. Approximately 0.9% of the company’s shares are short sold.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Anchor Investment Management LLC bought a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 2,898 shares of the company’s stock, valued at approximately $98,000.

iShares Genomics Immunology and Healthcare ETF Price Performance

NYSEARCA:IDNA traded down $0.48 during trading hours on Thursday, reaching $42.99. 84,968 shares of the company were exchanged, compared to its average volume of 73,272. The firm has a market cap of $337.47 million, a price-to-earnings ratio of 14.76 and a beta of 0.94. The stock has a 50 day simple moving average of $40.75 and a 200 day simple moving average of $33.15. iShares Genomics Immunology and Healthcare ETF has a 52-week low of $24.29 and a 52-week high of $43.79.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.